NCT05371964 - A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2028

Conditions

Myelofibrosis

Interventions

DRUG

Imetelstat sodium

Imetelstat sodium will be administered as intravenous (IV) every 28 days.

DRUG

Ruxolitinib

Ruxolitinib will be administered, orally (PO), twice daily (BID) in cohort B as the standard of care per local prescribing guidelines.

DRUG

Pacritinib

Pacritinib will be administered once daily (QD) or BID in cohort B as the standard of care per local prescribing guidelines.

DRUG

Momelotinib

Momelotinib will be administered once daily QD in cohort B as the standard of care per local prescribing guidelines.

DRUG

Fedratinib

Fedratinib will be administered QD in cohort B as the standard of care per local prescribing guidelines.

Trial Locations (8)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

33146

RECRUITING

University of Miami, Coral Gables

33612

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa

75020

RECRUITING

Texas Oncology, Denison

75702

RECRUITING

Texas Oncology, Tyler

91010

RECRUITING

City of Hope, Duarte

92618

RECRUITING

City of Hope, Irvine

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle